Hormone replacement therapy after menopause: where the controversy stands now
September 27, 2026 · 20 min read
Hormone and menopause specialists revisit the fear around hormone replacement therapy, weighing its benefits for symptoms, brain and body against the risks that made it controversial. This matters because outdated interpretations have kept many women from a treatment that may suit them.
The rules, numbers and steps worth keeping in front of you.
- Haver and Gottfried: the 2002 trial enrolled older women, average age 63, on synthetic hormones.
- Both: benefits cluster in women who start within about ten years of menopause, roughly 50 to 60.
- Haver: estrogen is better at prevention than cure; a late start may carry a small stroke risk.
- Haver: only 10% of women reporting menopause symptoms are offered any therapy.
- Haver: prefer patches, gels or sprays; avoid oral estrogen with any clotting history.
- Haver: women with a uterus must also take a progestogen; she prefers progesterone at night.
- Haver: local vaginal estrogen is extremely safe and helps recurrent urinary tract infections.
- Haver's contraindications: hormone-sensitive cancers, unexplained bleeding, active clots, severe liver disease.
- Haver: over 60 or ten years past menopause, screen first with a coronary calcium score or carotid ultrasound.
- Gottfried: hot flashes and night sweats are markers of heart, bone and brain change.
- Gottfried: get a hormone baseline in your 30s and a calcium score by 45.
- Huberman: be cautious with a family history of breast cancer, and get blood work.
- Mosconi: hormone therapy helps some women, not all; phytoestrogen foods are a gentler option.
- Decide with a qualified clinician who knows your personal and family history.
This is the short form. The full insight has every expert's reasoning, their own words and the sources.